AnaptysBio, Inc. (ANAB)
46.63
-0.77
(-1.62%)
USD |
NASDAQ |
Nov 20, 16:00
46.65
+0.02
(+0.04%)
After-Hours: 20:00
AnaptysBio Enterprise Value : 1.506B for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 1.506B |
| November 19, 2026 | 1.529B |
| November 18, 2026 | 1.518B |
| November 17, 2026 | 1.475B |
| November 16, 2026 | 1.479B |
| November 13, 2026 | 1.494B |
| November 12, 2026 | 1.540B |
| November 11, 2026 | 1.570B |
| November 10, 2026 | 1.558B |
| November 09, 2026 | 1.546B |
| November 06, 2026 | 1.500B |
| November 05, 2026 | 1.474B |
| November 04, 2026 | 1.532B |
| November 03, 2026 | 1.538B |
| November 02, 2026 | 1.514B |
| October 30, 2026 | 1.555B |
| October 29, 2026 | 1.566B |
| October 28, 2026 | 1.621B |
| October 27, 2026 | 1.595B |
| October 26, 2026 | 1.570B |
| October 23, 2026 | 1.568B |
| October 22, 2026 | 1.550B |
| October 21, 2026 | 1.545B |
| October 20, 2026 | 1.470B |
| October 19, 2026 | 1.584B |
| Date | Value |
|---|---|
| October 16, 2026 | 1.505B |
| October 15, 2026 | 1.568B |
| October 14, 2026 | 1.507B |
| October 13, 2026 | 1.474B |
| October 12, 2026 | 1.488B |
| October 09, 2026 | 1.485B |
| October 08, 2026 | 1.493B |
| October 07, 2026 | 1.476B |
| October 06, 2026 | 1.543B |
| October 05, 2026 | 1.582B |
| October 02, 2026 | 1.562B |
| October 01, 2026 | 1.565B |
| September 30, 2026 | 1.614B |
| September 29, 2026 | 1.603B |
| September 28, 2026 | 1.616B |
| September 25, 2026 | 1.622B |
| September 24, 2026 | 1.642B |
| September 23, 2026 | 1.615B |
| September 22, 2026 | 1.708B |
| September 21, 2026 | 1.738B |
| September 18, 2026 | 1.746B |
| September 17, 2026 | 1.742B |
| September 16, 2026 | 1.720B |
| September 15, 2026 | 1.731B |
| September 14, 2026 | 1.714B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 453.57M |
| Amgen, Inc. | 276.45B |
| Anika Therapeutics, Inc. | 158.39M |
| BioCryst Pharmaceuticals, Inc. | 2.302B |
| Imunon, Inc. | 6.224M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.876M |
| Revenue (Quarterly) | 30.27M |
| Total Expenses (Quarterly) | 26.40M |
| EPS Diluted (Quarterly) | 0.1105 |
| Gross Profit Margin (Quarterly) | 98.36% |
| Profit Margin (Quarterly) | 12.80% |
| Earnings Yield | 12.94% |
| Operating Earnings Yield | 8.19% |
| Normalized Earnings Yield | 12.94 |